From a therapeutic point of view, although PRTOACs have impressive activity in the targeting of BTK in CLL cells, over time compensatory molecules and pathways may arise that will oppose their activity, so in the future a combination of drugs should be studied. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.